Search results for "hazard ratio"

showing 10 items of 691 documents

Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma

2010

Summary Background : The tumor suppressor homologue p63 is expressed in basal and parabasal layers of intraoral mucosa. Full length transcripts with transactivational domain (TA forms) present with homology to p53 and implicate functions governing cell proliferation, differentiation and apoptosis control. To date studies show an increase of p63 expression in oral dysplasia and additionally high expression levels correlated with poor prognosis for patients with OSCC, whereas a possible link to radiation resistance of tumors has not been investigated yet. In the present study we tested the hypothesis for p63 being a marker of radioresistance and overall survival in OSCC. Methods : p63 Express…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyRadiation ToleranceRadioresistanceBiomarkers TumormedicineHumansSurvival analysisAgedMouth neoplasmProportional hazards modelbusiness.industryTumor Suppressor ProteinsHazard ratioMouth MucosaCancerMiddle AgedPrognosismedicine.diseaseImmunohistochemistrySurvival Analysisstomatognathic diseasesOncologyCarcinoma Squamous CellTrans-ActivatorsCancer researchImmunohistochemistryT-stageFemaleMouth NeoplasmsOral SurgerybusinessTranscription FactorsOral Oncology
researchProduct

Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer:The PanCareS…

2022

Late mortality of European five-year survivors of childhood or adolescent cancer has dropped over the last 60 years, but excess mortality persists. There is little information concerning secular trends in cause-specific mortality among older European survivors. PanCareSurFup pooled data from 12 cancer registries and clinics in 11 European countries from 77 423 five-year survivors of cancer diagnosed before age 21 between 1940 to 2008 followed for an average age of 21 years and a total of 1.27 million person-years to determine their risk of death using cumulative mortality, standardized mortality ratios (SMR), absolute excess risks (AER), and multivariable proportional hazards regression ana…

AdultMaleCancer ResearchSecond NeoplasmsAdolescentAdolescent cancercauses of deathEuropean03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsCause of DeathMedicineHumans030212 general & internal medicineCause specificChild610 Medicine & healthAgedExcess mortalitybusiness.industrycardiovascularsecond malignant neoplasmsHazard ratioCancersurvivors of childhood cancerMiddle Agedmedicine.diseaseConfidence interval3. Good healthOncologyEuropean; cardiovascular; causes of death; late mortality; second malignant neoplasms; survivors of childhood cancer030220 oncology & carcinogenesisChild Preschoollate mortalityFemaleRisk of deathbusiness360 Social problems & social servicesDemography
researchProduct

Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.

2019

Background/Aim: The aim of this study was to compare the ability of different lymph nodal staging systems to predict cancer recurrence in a multicenter European series of patients who underwent proctectomy after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Patients and Methods: Data on 170 consecutive patients undergoing proctectomy after neoadjuvant therapy for cT3-4 or cN+ rectal adenocarcinoma were retrieved from the European MRI and Rectal Cancer Surgery database. The prognostic role of the number of retrieved and examined nodes, nodal ratio, and log odds of positive lymph nodes (LODDS) was analyzed and compared by receiver operating characteristic curves, Pearson t…

AdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisColorectal cancerDisease-free survivalmedicine.medical_treatmentLODDSLocally advancedAdenocarcinomaDisease-Free SurvivalLog odds of positive lymph nodeRectal AdenocarcinomaMedicineHumansRectal cancerLog odds of positive lymph nodesNeoadjuvant therapyAgedNeoplasm StagingAged 80 and overReceiver operating characteristicddc:617business.industryRectal NeoplasmsHazard ratioGeneral MedicineNodal ratioChemoradiotherapyMiddle Agedmedicine.diseasePrognosisConfidence intervalNeoadjuvant TherapyOncologydisease-free survival; lodds; log odds of positive lymph nodes; neoadjuvant therapy; nodal ratio; rectal cancer; adenocarcinoma; adult; aged; aged 80 and over; disease-free survival; female; humans; lymph nodes; male; middle aged; neoplasm recurrence Local; Neoplasm Staging; Prognosis; Rectal Neoplasms; Chemoradiotherapy; Neoadjuvant TherapyNeoadjuvant therapyFemaleRadiologyLymph NodesNeoplasm Recurrence LocalbusinessAnticancer research
researchProduct

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

2005

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…

AdultMaleCancer Researchmedicine.medical_specialtyRandomization5-fluorouracil modulation; adjuvant chemotherapy; colorectal cancermedicine.drug_classColorectal cancerLeucovorincolorectal cancerAntimetaboliteGastroenterologyDisease-Free SurvivalFolinic acidRECTAL CANCER5-fluorouracil modulationCOLONInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseSurgeryadjuvant chemotherapyTreatment OutcomeLevamisoleOncologyChemotherapy AdjuvantFluorouracilVomitingFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With…

2012

Purpose This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m2 intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day …

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation AutologousGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleSettore MED/01 - Statistica MedicaBortezomib03 medical and health sciences0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationSurvival rateMultiple myelomaDexamethasoneAgedBortezomibbusiness.industryHazard ratioTranslational research Immune Regulation [ONCOL 3]Middle Agedmedicine.diseaseBoronic AcidsThalidomide3. Good healthSurgeryThalidomideTransplantationTreatment OutcomeOncologyPyrazines030220 oncology & carcinogenesisFemaleMultiple MyelomabusinessStem Cell Transplantation030215 immunologymedicine.drugJournal of Clinical Oncology
researchProduct

Association Between Individual and Combined SNPs in Genes Related to Innate Immunity and Incidence of CMV Infection in Seropositive Kidney Transplant…

2014

In this study, we assessed the association between single-nucleotide polymorphisms (SNPs) in seven candidate genes involved in orchestrating the immune response against cytomegalovirus (CMV) and the 12-month incidence of CMV infection in 315 CMV-seropositive kidney transplant (KT) recipients. Patients were managed either by antiviral prophylaxis or preemptive therapy. CMV infection occurred in 140 patients (44.4%), including 13 episodes of disease. After adjusting for various clinical covariates, patients harboring T-allele genotypes of interleukin-28B (IL28B) (rs12979860) SNP had lower incidence of CMV infection (adjusted hazard ratio [aHR]: 0.66; 95% confidence interval [CI]: 0.46-0.96; p…

AdultMaleCandidate geneGenotypeReceptors Cell SurfaceSingle-nucleotide polymorphismDiseasePolymorphism Single NucleotideImmune systemGenotypeOdds RatioHumansImmunology and AllergyMedicineSNPLectins C-TypePharmacology (medical)Prospective StudiesAllelesAgedProportional Hazards ModelsTransplantationbusiness.industryIncidenceInterleukinsHazard ratioTLR9Middle AgedKidney TransplantationImmunity InnateTransplant RecipientsCytomegalovirus InfectionsImmunologyKidney Failure ChronicFemaleInterferonsbusinessCell Adhesion MoleculesAmerican Journal of Transplantation
researchProduct

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.

2013

To validate current donor selection strategies based on previous international studies, we retrospectively analyzed 2646 transplantations performed for hematologic malignancies in 28 German transplant centers. Donors and recipients were high resolution typed for HLA-A, -B, -C, -DRB1, and -DQB1. The highest mortality in overall survival analysis was seen for HLA-A, -B, and DRB1 mismatches. HLA-DQB1 mismatched cases showed a trend toward higher mortality, mostly due to HLA-DQB1 antigen disparities. HLA incompatibilities at >1 locus showed additive detrimental effects. HLA mismatching had no significant effect on relapse incidence and primary graft failure. Graft source had no impact on surviv…

AdultMaleMultivariate analysisAdolescentmedicine.medical_treatmentImmunologyGraft vs Host DiseaseHematopoietic stem cell transplantationHuman leukocyte antigenHLA-C AntigensBiochemistry03 medical and health sciencesYoung Adult0302 clinical medicineimmune system diseasesTransplantation ImmunologyGermanymedicineHLA-DQ beta-ChainsHumansAlleleSurvival rateSurvival analysis030304 developmental biologyAgedRetrospective Studies0303 health sciencesHLA-A AntigensDonor selectionbusiness.industryHistocompatibility TestingHazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle AgedSurvival AnalysisTissue Donors3. Good healthSurvival RateHLA-B AntigensHematologic NeoplasmsHistocompatibilityImmunologyMultivariate AnalysisFemalebusiness030215 immunologyHLA-DRB1 ChainsBlood
researchProduct

Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis

2011

We tested for the presence of coronary calcifications in patients with chronic renal disease not on dialysis and studied its progression in 181 consecutive non-dialyzed patients who were followed for a median of 745 days. Coronary calcifications (calcium score) were tallied in Agatston units by computed tomography, and the patients were stratified into two groups by their baseline calcium score (100 U or less and over 100 U). Survival was measured by baseline calcium score and its progression. Cardiac death and myocardial infarction occurred in 29 patients and were significantly more frequent in those patients with calcium scores over 100 U (hazard ratio of 4.11). With a calcium score of 10…

AdultMaleNephrologymedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentMyocardial Infarctioncardiovascular events chronic kidney disease coronary calcificationCoronary Artery DiseaseKaplan-Meier EstimateCohort StudiesCoronary artery diseasecardiovascular eventsRisk FactorsCalcinosisInternal medicinemedicineHumansMyocardial infarctionRenal Insufficiency ChronicDialysisAgedSettore MED/14 - Nefrologiabusiness.industryHazard ratiocoronary calcificationCalcinosisMiddle AgedPrognosismedicine.diseasecardiovascular eventSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryNephrologyDisease ProgressionCardiologyFemaleOriginal Articlebusinesschronic kidney diseaseKidney diseaseCalcification
researchProduct

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

2017

<b><i>Background/Aim:</i></b> Individual components of the metabolic syndrome (MS) such as obesity or diabetes mellitus impair the prognosis of patients with hepatocellular carcinoma (HCC) following curative treatment approaches or transarterial therapies. The aim of this retrospective study was to assess the impact of these factors on the overall survival (OS) of patients with advanced HCC treated with sorafenib. <b><i>Methods:</i></b> Univariate and multivariate analyses were performed to assess the impact of individual components of the MS on the OS of 152 consecutive patients with advanced HCC treated with sorafenib. <b><i>Resu…

AdultMaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsYoung Adult03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansSurvival analysisAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overMetabolic Syndromebusiness.industryProportional hazards modelPhenylurea CompoundsLiver NeoplasmsHazard ratioGastroenterologyGeneral MedicineMiddle AgedSorafenibPrognosismedicine.diseaseSurvival Analysisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030220 oncology & carcinogenesisHepatocellular carcinomaMultivariate AnalysisFemale030211 gastroenterology & hepatologyMetabolic syndromebusinessDyslipidemiamedicine.drugDigestive Diseases
researchProduct

Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers

2019

Background The identification of appropriate biomarkers is essential to support important clinical decisions in patients with prostate cancer. The aim of our study was a systematic bioinformatical analysis of the mRNA expression of all genes available for the prostate adenocarcinoma cohort of The Cancer Genome Atlas (TCGA), regarding their potential prognostic and diagnostic role. Methods The study cohort comprises 499 patients (TCGA prostate cancer cohort). mRNA expression data were available for approx. 20,000 genes. The bioinformatical statistical pipeline addressed gene expression differences in tumor vs. benign prostate tissue (including gene set enrichment analysis, GSEA) in samples f…

AdultMaleOncologyBiochemical recurrencemedicine.medical_specialtyBiomedical ResearchMultivariate analysisBioinformaticsUrology030232 urology & nephrologyAdenocarcinomalcsh:RC870-923PrognosticCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansDiagnosticEpigeneticsAgedProstate cancerProportional hazards modelbusiness.industryHazard ratiomRNA expressionProstatic NeoplasmsGeneral MedicineMiddle Agedlcsh:Diseases of the genitourinary system. UrologyPrognosismedicine.diseaseGene Expression Regulation NeoplasticReproductive Medicine030220 oncology & carcinogenesisCohortBiomarker (medicine)businessBiomarkersResearch ArticleBMC Urology
researchProduct